T1	Condition 7 15	melanoma
T2	Qualifier 0 6	HLA-A2
R1	Has_qualifier Arg1:T1 Arg2:T2	
T3	Condition 40 53;68 78	loco-regional metastasis
T4	Condition 57 78	lymph node metastasis
T5	Condition 80 95	transit nodules
T6	Qualifier 100 121	surgically resectable
T7	Negation 96 99	not
R2	Has_negation Arg1:T6 Arg2:T7	
R3	Has_qualifier Arg1:T5 Arg2:T6	
T8	Procedure 100 110	surgically
R4	multi Arg1:T6 Arg2:T8	
T9	Condition 147 166	visceral metastasis
T10	Condition 134 143;156 166	cutaneous metastasis
*	OR T9 T10
T11	Qualifier 123 133	measurable
T12	Scope 134 166	cutaneous or visceral metastasis
R5	Has_qualifier Arg1:T12 Arg2:T11	
T13	Observation 200 214	MART-1 antigen
T14	Observation 192 199;207 214	Melan-A antigen
T15	Procedure 220 232	chemotherapy
T16	Negation 217 219	No
T17	Drug 255 263	Deticene
T18	Negation 244 254	except for
R7	Has_negation Arg1:T17 Arg2:T18	
T19	Temporal 269 308	before the first T cell clones infusion
T20	Reference_point 276 308	the first T cell clones infusion
R8	Has_index Arg1:T19 Arg2:T20	
R9	Has_temporal Arg1:T17 Arg2:T19	
R10	AND Arg1:T15 Arg2:T17	
T21	Procedure 313 325	radiotherapy
T22	Procedure 329 342	immunotherapy
*	OR T21 T22 T15
T23	Temporal 343 378	in the last 4 weeks before infusion
T24	Reference_point 370 378	infusion
R11	Has_index Arg1:T23 Arg2:T24	
T25	Condition 390 398	melanoma
T26	Temporal 409 428	during the protocol
T27	Procedure 399 408	treatment
R12	causal Arg1:T27 Arg2:T25	
R13	Has_temporal Arg1:T27 Arg2:T26	
T28	Observation 431 446	Life expectancy
T29	Value 457 478	greater than 6 months
R14	Has_value Arg1:T28 Arg2:T29	
T30	Measurement 500 509	Karnowsky
T31	Value 510 525	greater than 80
R15	Has_value Arg1:T30 Arg2:T31	
T32	Measurement 527 531	ECOG
T33	Value 534 543	0, 1 or 2
R16	Has_value Arg1:T32 Arg2:T33	
T34	Measurement 577 580	HIV
T35	Value 564 572	negative
T36	Measurement 591 602	C hepatitis
T37	Measurement 585 586;593 602	B hepatitis
T38	Scope 577 602	HIV and B and C hepatitis
R17	Has_value Arg1:T38 Arg2:T35	
T39	Measurement 658 668	leucocytes
T40	Value 669 692	³ 2000 elements per mm3
R18	Has_value Arg1:T39 Arg2:T40	
T41	Measurement 694 704	hemoglobin
T42	Value 705 715	³ 10.5g/dl
T43	Measurement 717 726	platelets
T44	Value 727 744	³ 100 000 per mm3
R19	Has_value Arg1:T43 Arg2:T44	
T45	Measurement 746 782	phosphatases alcalines transaminases
T46	Value 783 818	£ 1 time 1/2 compared to the normal
R20	Has_value Arg1:T45 Arg2:T46	
T47	Observation 821 844	Signed informed consent
T48	Scope 220 342	chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy
R6	Has_temporal Arg1:T48 Arg2:T23	
R21	Has_negation Arg1:T48 Arg2:T16	
*	OR T3 T4
T49	Temporal 627 656	at the beginning of the study
T50	Reference_point 630 656	the beginning of the study
R22	Has_index Arg1:T49 Arg2:T50	
T51	Scope 658 818	leucocytes ³ 2000 elements per mm3, hemoglobin ³ 10.5g/dl, platelets ³ 100 000 per mm3, phosphatases alcalines transaminases £ 1 time 1/2 compared to the normal
R23	Has_temporal Arg1:T51 Arg2:T49	
